Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
TScan Therapeutics, Inc. | 10%+ Owner | Pre-funded Warrant (right to buy) | 5M | $35.6M | $7.13 | Apr 19, 2024 | Indirect |
TScan Therapeutics, Inc. | 10%+ Owner | Common stock, $0.0001 par value per share | 5.23M | $22.7M | $4.34 | Nov 15, 2024 | Indirect |
Passage BIO, Inc. | 10%+ Owner | Common Stock | 8.88M | $5.96M | $0.67 | Nov 27, 2024 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PASG | Passage BIO, Inc. | Nov 25, 2024 | 3 | $285K | 4 | Nov 27, 2024 | 10%+ Owner |
TCRX | TScan Therapeutics, Inc. | Nov 15, 2024 | 1 | $4.11K | 4 | Nov 19, 2024 | 10%+ Owner |
PASG | Passage BIO, Inc. | Aug 7, 2024 | 0 | $0 | 3 | Aug 9, 2024 | 10%+ Owner |
TCRX | TScan Therapeutics, Inc. | Apr 19, 2024 | 1 | $35.6M | 4 | Apr 23, 2024 | 10%+ Owner |
TCRX | TScan Therapeutics, Inc. | May 31, 2023 | 3 | -$64K | 4 | Jun 2, 2023 | 10%+ Owner |
TCRX | TScan Therapeutics, Inc. | May 31, 2023 | 0 | $0 | 3 | Jun 2, 2023 | 10%+ Owner |